サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：頭頂葉炎治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1374778

頭頂葉炎治療の世界市場-2023年～2030年

Global Pars Planitis Treatment Market -2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
頭頂葉炎治療の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界の傍扁平上皮炎治療市場は、そのダイナミクスに影響を与える様々な要因によって、長年にわたって大きな成長と変貌を遂げてきました。傍扁平上皮炎と呼ばれる持続性の中間ぶどう膜炎は、全身性の病気や感染症とは無関係です。扁平上皮炎患者が症状を経験することは稀ですが、浮遊物や視力障害に言及することはあります。通常、痛みや羞明はありません。

特に新興経済諸国における政府投資と研究開発は、副腎皮質ステロイドや免疫抑制剤のような新薬の利用を引き続き促進し、世界の傍扁平上皮炎治療市場を押し上げると思われます。それぞれの革新的な治療法は複数の研究者によって開発され、現在試験中です。

市場促進要因：市場抑制要因

資金調達と買収の増加

新興経済諸国は、高額の投資、所得水準、インフラ整備に牽引され、ヘルスケア分野の改善において急速な成長を遂げています。いくつかの国では、研究の高まりにより、副鼻腔炎治療に対する大きな需要が発生しています。さまざまな国間での共同研究、買収、技術的進歩を伴う製品発売は、市場の成長を促進する重要な要因です。

2023年7月3日、Viatrisの世界バイオシミラー事業は最近Biocon Biologicsに買収され、同社は米国、欧州、その他100カ国以上で多数のバイオシミラーライセンスも取得しています。バイオコン・バイオロジクス社は、ヴィアトリス社のバイオシミラー事業を買収したことにより、患者や医療関係者に対し、より入手しやすく安価な治療選択肢を提供することができるようになりました。

バイオコン・リミテッドの一部門であるバイオコン・バイオロジクス社（BBL）は、ヒュミラ（アダリムマブ）のバイオシミラーであるヒュリオ（アダリムマブ-fkjp）注射剤が、欧州で5年間、カナダで2年間使用された後、米国で患者が使用できるようになったと発表しました。

さらに、いくつかの開発目的のために、高レベルの研究による新規技術の利用が増加しています。傍扁平上皮炎患者の増加と革新的な治療開発のための研究の増加は、傍扁平上皮炎治療市場の成長を促進する主な要因です。

傍扁平上皮炎治療薬に関連する副作用

治療にかかわらず、扁平上皮随伴炎の患者は多発性硬化症に罹患する可能性が高く、抗TNF薬は脱髄を誘発する可能性があります。したがって、扁平上皮随伴炎の患者に抗TNF薬を投与する前には、最大限の注意を払い、リスクとベネフィットの比率を評価すべきです。

扁平上皮炎はインターフェロンによる治療にも成功しているが、副作用としてうつ病や自殺念慮がみられることがあります。白内障と緑内障は、最も頻繁に投与されるステロイドの副作用です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 資金調達と企業買収の増加
      • 技術的進歩と開発の高まり
    • 抑制要因
      • 副鼻腔炎治療薬に伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • SWOT分析
  • 特許分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 医薬品別

  • 副腎皮質ステロイド
    • プレドニン（デルタゾン、メチコルテン、オラゾン）
    • トリアムシノロン（アムコート）
    • プレドニゾロン1％（プレドフォルテ）
  • 免疫抑制剤
    • メトトレキサート（フォレックスPFS、リウマトレックス）
    • ミコフェノラート（セルセプト、MMF、マイフォルティック）
    • シクロスポリン（サンディミュン、ネオーラル）
    • アザチオプリン（イムラン）
  • ヒスタミンH2受容体拮抗薬
    • シメチジン（タガメット）
    • ラニチジン（ザンタック）
  • 胃ポンプ阻害薬
    • オメプラゾール（プリロセック）
    • ランソプラゾール（プレバシド）
    • エソメプラゾール・マグネシウム（ネキシウム）
  • 腫瘍壊死因子（TNF）阻害薬（DMARDs）
    • アダリムマブ（アダリムマブ-アト、アムジェビタ、ヒュミラ）

第8章 投与経路別

  • 経口
  • 静脈内投与
  • その他

第9章 販売チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Teva Pharmaceutical Industries Ltd.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • AbbVie Inc.（Allergan）
  • Aurobindo Pharma USA
  • Pfizer Inc.
  • Genentech, Inc.
  • Novartis AG
  • Rosemont Pharmaceuticals Limited
  • Xiromed
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim Pharmaceuticals, Inc.

第13章 付録

目次
Product Code: PH7183

Overview

The global pars planitis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. A persistent intermediate uveitis called pars planitis has not been connected with any systemic illness or infection. Although pars planitis patients rarely experience symptoms, they could mention floaters or impaired vision. There is typically no pain or photophobia.

Government investments and research, particularly in developing economies, will continue to drive utilization of novel medicines like corticosteroids or immunosuppressives and boost the global pars planitis treatment market. The respective innovative treatment are being developed by several researchers and currently are under trials.

Market Dynamics: Drivers & Restraints

Growing funding and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for pars planitis treatment owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On July 3, 2023, the global biosimilars business of Viatris was recently acquired by Biocon Biologics, which has also obtained numerous biosimilar licenses in the United States, Europe, and more than 100 other nations. Biocon Biologics can now assist in supplying patients and medical professionals with additional accessible and inexpensive treatment alternatives thanks to the acquisition of Viatris' biosimilars business.

After five years of use in Europe and two years in Canada, Biocon Biologics Ltd (BBL), a division of Biocon Ltd, announced that HULIO (adalimumab-fkjp) injectable, a biosimilar to Humira (adalimumab), has become accessible to patients in the United States.

Furthermore, the rising utilization of novel technology with high level of research for the several development purposes. Rising pars planitis cases and increasing research for innovative treatment development will be a major factor driving the growth of the pars planitis treatment market.

Side effects associated with the pars planitis treatment drugs

Regardless of treatment, patients with pars planitis could be at a greater likelihood for getting multiple sclerosis and anti-TNF Drugs may predispose to demyelination. Therefore, utmost caution should be utilized and the risk-benefit ratio should be assessed before administering an anti-TNF drug to a patient with pars planitis.

Pars planitis has also been successfully treated with interferon, however side effects can include depression or suicidal thoughts. Cataracts and glaucoma are the side effects of steroids that are most frequently administered.

Segment Analysis

The global pars planitis treatment market is segmented based on drugs, route of administration, distribution channel and region.

Corticosteroids segment accounted for approximately 37% of market share

Prednisolone sodium phosphate or acetate topical treatment, both of which are 1%. Along with oral prednisone, periocular injections with corticosteroids are also beneficial. Treatment options include intravitreal injections of triamcinolone acetonide.

Steroid medications can be used to treat the majority of intermediate uveitis cases. Prednisolone is a medication that is frequently used. Steroids act by interfering with the immune system's regular operation so that it no longer secretes the substances that cause inflammation.

On November 17, 2021, the U.S. Food and Drug Administration has given final approval to Aurobindo Pharma Limited's Abbreviated New Drug Application for Prednisone Tablets USP, 1mg. Prednisone Tablets USP, 1mg from Aurobindo Pharma are a reference-listed drug (RLD) identical to Meticorten Tablets from Schering Corp Sub Schering Plough Corp.

Geographical Penetration

North America accounted for around 36% of market share in 2022

Due to the rising need for pars planitis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for pars planitis treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different classes of drug, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of pars planitis treatment market share of this region. The market in this area is growing as people become more aware of various novel approved medicines. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global pars planitis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for pars planitis treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating pars planitis treatment demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global pars planitis treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various medicines, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and pharmaceutical industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for pars planitis treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global pars planitis treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for inovative treatment.

Key Developments

  • On March 21, 2023, the US Food and Drug Administration (FDA) has approved a high-concentration formulation (HCF) which is citrate-free of Sandoz's biosimilar Hyrimoz (adalimumab-adaz) injection, according to the company, a leader in generic drugs and biosimilars. The reference drug Humira* (adalimumab) covers seven indications, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, and plaque psoriasis. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat these conditions.
  • On March 25, 2021, Omeprazole Prolonged Release Capsules, 20mg, a generic version of Prilosec, have been launched, according to Xiromed LLC, the generic branch of Insud Pharmaceuticals based in New Jersey. Proton pump inhibitors like Prilosec are prescribed for treating gastroesophageal reflux disease (GERD) in both adults and children as well as for treating duodenal and gastric ulcers in adults and maintaining the healing of erosive esophagitis.

Competitive Landscape

The major global players in the market include: Teva Pharmaceutical Industries Ltd., AbbVie Inc. (Allergan), Aurobindo Pharma USA, Pfizer Inc., Genentech, Inc., Novartis AG, Rosemont Pharmaceuticals Limited, Xiromed, Takeda Pharmaceutical Company Limited and Boehringer Ingelheim Pharmaceuticals, Inc. among others.

Why Purchase the Report?

  • To visualize the global pars planitis treatment market segmentation based on drugs, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of pars planitis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global pars planitis treatment market report would provide approximately 61 tables, 59 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drugs
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing funding and acquisitions
      • 4.1.1.2. Rising technological advancements and developments
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the pars planitis drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. SWOT Analysis
  • 5.6. Patent Analysis
  • 5.7. Russia-Ukraine War Impact Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drugs

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 7.1.2. Market Attractiveness Index, By Drugs
  • 7.2. Corticosteroids*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Prednisone (Deltasone, Meticorten, Orasone)
    • 7.2.4. Triamcinolone (Amcort)
    • 7.2.5. Prednisolone 1% (Pred Forte)
  • 7.3. Immunosuppressives
    • 7.3.1. Methotrexate (Folex PFS, Rheumatrex)
    • 7.3.2. Mycophenolate (CellCept, MMF, Myfortic)
    • 7.3.3. Cyclosporine (Sandimmune, Neoral)
    • 7.3.4. Azathioprine (Imuran)
  • 7.4. Histamine H2-Receptor Antagonist
    • 7.4.1. Cimetidine (Tagamet)
    • 7.4.2. Ranitidine (Zantac)
  • 7.5. Gastric Pump Inhibitors
    • 7.5.1. Omeprazole (Prilosec)
    • 7.5.2. Lansoprazole (Prevacid)
    • 7.5.3. Esomeprazole magnesium (Nexium)
  • 7.6. Tumor Necrosis Factor (TNF) inhibitors (DMARDs)
    • 7.6.1. Adalimumab (Adalimumab-atto, Amjevita, Humira)

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Intravenous
  • 8.4. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Teva Pharmaceutical Industries Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. AbbVie Inc. (Allergan)
  • 12.3. Aurobindo Pharma USA
  • 12.4. Pfizer Inc.
  • 12.5. Genentech, Inc.
  • 12.6. Novartis AG
  • 12.7. Rosemont Pharmaceuticals Limited
  • 12.8. Xiromed
  • 12.9. Takeda Pharmaceutical Company Limited
  • 12.10. Boehringer Ingelheim Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us